This case report could provide more information for therapeutic strategy selecting of NSCLC patients harboring rare EGFR mutations.<h4>Conclusion</h4>We report for the first time the long-lasting and stable disease control with Almonertinib for EGFR p.V774M/p.L833V compound mutations treatment, hoping to provide more clinical case references for the treatment of rare compound mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.